{"title":"从历史的角度看ximelagatran的发现。","authors":"David Gustafsson","doi":"10.1055/s-2005-916161","DOIUrl":null,"url":null,"abstract":"<p><p>The oral direct thrombin inhibitor ximelagatran is the first oral anticoagulant since the introduction of the vitamin K antagonists in the early 1940s. A comparison of the discovery and early clinical development of the two classes of oral anticoagulants reveals some similarities but also several differences that illustrate the change in drug discovery over the last half century.</p>","PeriodicalId":87139,"journal":{"name":"Seminars in vascular medicine","volume":"5 3","pages":"227-34"},"PeriodicalIF":0.0000,"publicationDate":"2005-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1055/s-2005-916161","citationCount":"5","resultStr":"{\"title\":\"Discovery of ximelagatran in an historical perspective.\",\"authors\":\"David Gustafsson\",\"doi\":\"10.1055/s-2005-916161\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The oral direct thrombin inhibitor ximelagatran is the first oral anticoagulant since the introduction of the vitamin K antagonists in the early 1940s. A comparison of the discovery and early clinical development of the two classes of oral anticoagulants reveals some similarities but also several differences that illustrate the change in drug discovery over the last half century.</p>\",\"PeriodicalId\":87139,\"journal\":{\"name\":\"Seminars in vascular medicine\",\"volume\":\"5 3\",\"pages\":\"227-34\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2005-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1055/s-2005-916161\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in vascular medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1055/s-2005-916161\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in vascular medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-2005-916161","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Discovery of ximelagatran in an historical perspective.
The oral direct thrombin inhibitor ximelagatran is the first oral anticoagulant since the introduction of the vitamin K antagonists in the early 1940s. A comparison of the discovery and early clinical development of the two classes of oral anticoagulants reveals some similarities but also several differences that illustrate the change in drug discovery over the last half century.